Copenhagen, DenmarkMay 11, 2026 /PRNewswire/ — In the first quarter of 2026, Novonesis achieved strong organic sales growth of 7%.
Ester Baiget, President and CEO of Novonesis, stated:
“We delivered 7% organic sales growth against a high comparable base, marking a strong start to the new year. Growth was seen across all sales areas, as well as in both developed and emerging markets. Our performance quarter after quarter demonstrates the resilience and stability of our business model. Despite increasing global uncertainties, we remain confident in our full-year outlook and our 2030 targets, including achieving a 6-9% compound annual growth rate in organic sales. As the world continues to evolve, the relevance of biological solutions across various industries is steadily increasing, driving growing market demand.”
Key highlights for the first quarter of 2026:
- Broad-based growth across multiple business segments drove organic sales growth of 7%.
- Food & Health Biosolutions achieved organic growth of 9%, while Earth Health Biosolutions grew by 5%.
- Developed markets saw organic growth of 8%, and emerging markets grew by 4%.
- Successfully completed an inaugural bond issuance of €1.7 billion to refinance bridge loans.
- Acquired a production facility in Thailand to support growth initiatives.
- Full-year 2026 outlook remains unchanged: Organic sales growth is expected to be in the range of 5-7%.